Needham Reiterates Buy on Vaxcyte, Maintains $95 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer reiterates a Buy rating on Vaxcyte (NASDAQ:PCVX) and maintains a $95 price target.
June 28, 2024 | 10:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Vaxcyte and maintains a $95 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $95 price target by a reputable analyst suggests strong confidence in Vaxcyte's future performance. This is likely to positively impact the stock price in the short term as investors may view this as a bullish signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100